Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes

Cardiovascular Research

Volumn 47, Issue 3, 2000, Pages 549-555

  Hung, Li Man ^a   Chen, Jan Kan ^b   Huang, Shiang Suo ^a   Lee, Ren Shen ^c   Su, Ming Jai ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Arrhythmia, mechanisms; Free radicals; Ischemia; Nitric oxide; Reperfusion

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; ANTIARRHYTHMIC AGENT; ANTIOXIDANT; LACTATE DEHYDROGENASE; NATURAL PRODUCT; NITRIC OXIDE; RESVERATROL;

ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GRAPE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; FREE RADICAL SCAVENGERS; HEART RATE; L-LACTATE DEHYDROGENASE; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; STATISTICS, NONPARAMETRIC; STILBENES; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 0034682983     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00102-4     Document Type: Article

References (45)

1. Renaud S., de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 339:1992;1523-1526.
2. Renaud S.C., Gueguen R., Schenker J., d'Houtaud A. Alcohol and mortality in middle-aged men from Eastern France. Epidemiology. 9:1998;184-188.
3. Constant J. Alcohol, ischemic heart disease, and the French paradox. Coron Artery Dis. 8:1997;645-649.
4. Arichi H., Kimura Y., Okuda H., Baba K., Kozawa M., Arichi S. Effects of stilbene components of the roots of polygonum on lipid metabolism. Chem Pharm Bull. 30:1982;1766-1770.
5. Kimura Y., Okuda H., Arichi S. Effects of stilbene derivatives on arachidonate metabolism in leukocytes. Biochim Biophys Acta. 837:1985;209-212.
6. Ragazzi E., Froldi G., Fassina G. Resveratrol activity on guinea pig isolated trachea from normal and albumin-sensitized animals. Pharmacol Res Commun. 20:1988;79-82.
7. Bertelli A.A., Giovannini L., Giannessi D., et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React. 17:1995;1-3.
8. Jayatilake G.S., Jayasuriya H., Lee E.S., et al. Kinase inhibitors polygonum cuspidatum. J Nat Prod. 56:1993;1805-1810.
9. Rotondo S., Rajtar G., Manarinis S., et al. Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br J Pharmacol. 123:1998;1691-1699.
10. Frankel E.N., Waterhouse A.L., Kinsella J.E. Inhibition of human LDL oxidation by resveratrol. Lancet. 341:1993;1103-1104.
11. Hearse D.J. Myocardial ischemia: can we agree on a definition for the 21st century? Cardiovasc Res. 28:1994;1737-1744.
12. Robicsek F., Schaper J. Reperfusion injury: fact or myth? J Cardiac Surg. 12:1997;133-137.
13. Zweier J.L. Measurement of superoxide-derived free radicals in the reperfused heart: evidence for a free radical mechanism of reperfusion injury. J Biol Chem. 263:1988;1353-1357.
14. Brooks W.W., Conarad C.H., Morgan J.P. Reperfusion induced arrhythmias following ischemia in intact rat heart: role of intracellular calcium. Cardiovasc Res. 29:1995;536-542.
15. Fitzpatrick D.F., Hirschfield S.L., Coffey R.G. Endothelium-dependent vasorelaxing activity of wine and other grape products. Am J Physiol. 265:1993;H774-H778.
16. Thakkar K., Geahlen R.L., Cushman M. Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol. J Med Chem. 36:1993;2950-2955.
17. Mellors A., Tappel A.L. The inhibition of mitochondria by ubiquinone and ubiquinol. J Biol Chem. 241:1966;4353-4356.
18. Smith, 3rd E.F., Griswold D.E., Egan J.W., Hillegass L.M., Dimartino M.J. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505. J Cardiovasc Pharm. 13:1989;715-722.
19. Walker M.J., Curtis M.J., Hearse D.J., et al. The Lambeth Conventions: quidelines for the study of arrhythmias in ischemia infarction, and reperfusion. Cardiovasc Res. 22:1988;447-455.
20. Archer J. Measurement of nitric oxide in biological models. FASEB J. 7:1993;349-360.
21. Manning A.S., Coltart D.J., Hearse D.J. Ischemia and reperfusion-induced arrhythmias in the rat: effects of xanthine oxidase inhibition with allopurinol. Circ Res. 55:1984;545-548.
22. Kusama Y., Bernier M., Hearse D.J. Exacerbation of reperfusion arrhythmias by sudden oxidant stress. Circ Res. 67:1990;481-489.
23. Corr P.B., Witkowski F.X. Potential electrophysiologic mechanisms responsible for dysrhythmias associated with reperfusion of ischemic myocardium. Circulation. 68:1983;116-124.
24. Levitsky J., Gurell D., Frishman W.H. Sodium ion/hydrogen ion exchange inhibition: a new pharmacologic approach to myocardial ischemia and reperfusion injury. J Clin Pharmacol. 38:1998;887-897.
25. Pierce G.N., Czubryt M.P. The contribution of ionic imbalance to ischemia-reperfusion-induced injury. J Mol Cell Cardiol. 27:1995;53-63.
26. Du Toit E.F., Muller C.A., McCarthy J., Opie L.H. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia-reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther. 290:1999;505-514.
27. de Jong J.W., Cargnoni A., Bradamante S., et al. Intermittent vs. continuous ischemia decelerates adenylate breakdown and prevents norepinephrine release in reperfused rabbit heart. J Mol Cell Cardiol. 27:1995;659-671.
28. Das D.K., Engelman R.M., Rousou J.A., Breyer R.H., Otani H., Lemeshow S. Role of membrane phospholipids in myocardial injury induced by ischemia and reperfusion. Am J Physiol. 251:1986;H71-H79.
29. Montrucchio G., Alloatti G., Mariano F., et al. Role of platelet-activating factor in polymorphonuclear neutrophil recruitment in reperfused ischemic rabbit heart. Am J Pathol. 142:1993;471-480.
30. Flesch M., Maack C., Cremers B., Bäumer A.T., Südkamp M., Böhm M. Effect of β-blockers on free radical-induced cardiac contractile dysfunction. Circulation. 100:1999;346-353.
31. + and acidosis on the intracellular sodium activity and resting potential in guinea pig papillary muscle. Circ Res. 58:1986;249-256.
32. Pogwizd S.M., Corr P.B. Reentrant and Nonreentrant mechanisms contribute to arrhythmogenesis during early myocardial ischemia: Results using three-dimensional mapping. Circ Res. 61:1987;352-371.
33. Hawes E.M., Watts J.A. Xanthine oxidase/dehydrogenase release following ischemia in isolated rat hearts. Am J Cardiovasc Pathol. 4:1993;326-335.
34. Wang P., Chen H., Win H., et al. Overexpression of human copper, zinc-superoxide dismutase (SOD 1) prevents postischemic injury. Proc Natl Acad Sci USA. 98:1998;4556-4560.
35. Kramer J.H., Misik V., Weglicki W.B. Magnesium-deficiency potentiates free radical production associated with postischemic injury to rat hearts: vitamin E affords protection. Free Radical Bio Med. 16:1994;713-723.
36. Ray P.S., Maulik G., Cordis G.A., Bertelli A.A.E., Bertelli A., Das D.K. The red wine antioxidant resveratrol protects isolated rat heats from ischemia reperfusion injury. Free Radical Bio Med. 27:1999;160-169.
37. Zweier J.L., Kuppusamy P., Williams R., et al. Measurement and characterization of postischemic free radical generation in the isolated perfused heart. J Biol Chem. 264:1989;18890-18895.
38. Belguendouz L., Fremont L., Linard A. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol. 53:1997;1347-1355.
39. Bertelli A.A.E., Giovannini L., Stradi R., Urien S., Tillement J.P., Bertelli A. Kinetics of trans- and cis-resveratrol (3,4′,5-trihydroxystilbene) after red wine oral administration in rats. Int J Clin Pharmacol Res. XVI:1996;77-81.
40. Bertelli A., Bertelli A.A.E., Gozzini A., Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drug Exp Clin Res. 24:1998;133-138.
41. Maulik N., Engelman D.T., Watanabe M., et al. Nitric oxide signaling in ischemic heart. Cardiovasc Res. 30:1995;593-601.
42. Wang P., Wzeier J.L. Measurement of nitric oxide and peroxynitrite generation in the postischemic heart: evidence for peroxynitrite-mediated reperfusion injury. J Biol Chem. 271:1996;29223-29230.
43. Weiss H.R., Rodriguez E., Tse J., Scholz P.M. Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts. Clin Exp Pharmacol Physiol. 21:1994;607-614.
44. Nakanishi K., Vinten-Johansen J., Lefer D.J., et al. Intracoronary L-arginine during reperfusion improves endothelial function and reduces infarct size. Am J Physiol. 263:1992;H1650-H1658.
45. Qiu Y., Rizvi A., Tand X-L, et al. Nitric oxide triggers late preconditioning against myocardial infarction in conscious rabbits. Am J Physiol. 273:1997;H2931-H2936.